European Pharmaceutical Review

JULY 20, 2023

In June 2023, an array of leading voices in AAV development for cell and gene therapies articulated the current challenges and their optimism for the rapidly advancing sector at the Cell and Gene Therapy Summit event in London. For cell and gene therapy, a “big issue” she stated, was the complexity of manufacturing.

Consulting 55

Consulting Side effects Manufacturing Safety 55

Pharmaceutical Technology

JANUARY 25, 2023

According to a whitepaper from contract research, development and manufacturing organisation Syngene, PROTACs are effective against “undruggable” targets such as transcription factors, and scaffolding proteins that cannot be otherwise targeted by the traditional small molecule inhibitors.

Side effects 52

Side effects Leads Safety Manufacturing 52

Quantified

MAY 2, 2024

They also need to know which conditions each medication treats and accurately convey their therapeutic benefits, safety profiles, possible side effects, and the most recent data available related to patient outcomes. That’s a lot of information.

Training 52

Training Sales Pharma Sales Management 52

Medico Reach

FEBRUARY 8, 2023

The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. AI can lead to faster research, combining and extracting data into usable formats, making clinical trials more efficient and saving time.

Pharma 52

Pharma Medicine Marketing Prospecting 52

PM360

JULY 13, 2023

1 Healthline Media’s new solution, Rx Savings Program, is an interactive experience on its drug information pages that drives users to take action with manufacturer drug savings programs, helping them better afford and adhere to treatment. Nearly three in five people have experienced out-of-pocket prescription costs they couldn’t afford.

Education 89

Education Medical Media Patients 89

European Pharmaceutical Review

AUGUST 14, 2023

The company’s lead candidate, C21, is an angiotensin II type 2 receptor agonist (ATRAG). This data, together with a favourable safety profile, make C21 a potential game-changer for IPF patients, particularly those who are currently not treated due to the side effects of the available drugs, according to Dalsgaard.

Pharma 83

Pharma Side effects Patients Manufacturing 83

PM360

JULY 13, 2023

However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. What Other Developments Within Oncology Excite You? What Is Your Company Currently Working On?

Patients 98

Patients Engineering Side effects Leads 98

PM360

NOVEMBER 29, 2022

Researchers are diligently creating new methods for cell and gene editing as well as therapeutic delivery to increase safety, accessibility, and affordability. The advanced therapy industry has shown great promise in treating rare and genetic diseases, but have encountered roadblocks in safety, affordability, and accessibility.

Patients 111

Patients Safety Marketing Side effects 111

European Pharmaceutical Review

DECEMBER 27, 2023

2,3 Clinical implementation of CAR T-cell technology requires a reproducible T-cell manufacturing platform, which necessitates effective gene-transfer tools and T-cell culture conditions. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.

Manufacturing 79

Manufacturing Food and Drug Administration Patients Pharma 79

World of DTC Marketing

SEPTEMBER 28, 2020

Will it lead to an early approval with limited testing or will J&J ensure the vaccine goes thru thorough testing? government to manufacture 100 million doses of its investigational COVID-19 vaccine. OK, NOW WHAT? J&J’s COVID vaccine is being promoted by the media to have a 98% immune system response.

Food and Drug Administration 163

Food and Drug Administration Pharma Side effects Food 163

Pharmaceutical Technology

FEBRUARY 23, 2023

Many compounds present sub-optimal pharmacokinetic (PK) data (either predicted from in-vitro and pre-clinical data or measured in the clinic), such as poor exposure (leading to high doses), large variability, short half-life requiring more than once-a-day dosing, or C max -related adverse events (AEs).

Food and Drug Administration 98

Food and Drug Administration Pharmaceutical Food Side effects 98